OBJECTIVE: To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA. METHODS: Twelve patients with rapidly destructive and 28 patients with slowly progressive hip OA were included in a prospective, cross sectional case-control study. Urinary levels of C-terminal crosslinking telopeptide of collagen type II (CTX-II) as a marker of cartilage degradation were measured by an ELISA, and urinary free deoxypyridinoline (free DPD), a marker of bone resorption, was measured by high performance liquid chromatography. One x ray evaluation of the hips and urine samples was made in all patients when the diagnosis of OA was established. RESULTS: Patients with hip OA had higher mean (SD) urinary CTX-II levels than 65 healthy age matched controls (492 (232) v 342 (141), p<0.001), but no significant difference was seen for urinary free DPD (p=0.30). Increased urinary CTX-II, but not urinary free DPD, correlated significantly with decreased minimum joint space width assessed by radiograph of the hip. Mean urinary CTX-II levels were significantly higher in patients with rapidly progressive OA than in the slowly progressive group (612 (218) v 441 (221), p=0.015), whereas no significant difference of urinary free DPD was seen between the two groups (p=0.55). CONCLUSION: Patients with hip OA have increased CTX-II degradation as assessed by a new urinary marker. Increased urinary CTX-II levels are associated with rapidly destructive disease, suggesting that this marker might be useful in identifying patients with hip OA at high risk for rapid progression of joint damage.
OBJECTIVE: To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA. METHODS: Twelve patients with rapidly destructive and 28 patients with slowly progressive hip OA were included in a prospective, cross sectional case-control study. Urinary levels of C-terminal crosslinking telopeptide of collagen type II (CTX-II) as a marker of cartilage degradation were measured by an ELISA, and urinary free deoxypyridinoline (free DPD), a marker of bone resorption, was measured by high performance liquid chromatography. One x ray evaluation of the hips and urine samples was made in all patients when the diagnosis of OA was established. RESULTS:Patients with hip OA had higher mean (SD) urinary CTX-II levels than 65 healthy age matched controls (492 (232) v 342 (141), p<0.001), but no significant difference was seen for urinary free DPD (p=0.30). Increased urinary CTX-II, but not urinary free DPD, correlated significantly with decreased minimum joint space width assessed by radiograph of the hip. Mean urinary CTX-II levels were significantly higher in patients with rapidly progressive OA than in the slowly progressive group (612 (218) v 441 (221), p=0.015), whereas no significant difference of urinary free DPD was seen between the two groups (p=0.55). CONCLUSION:Patients with hip OA have increased CTX-II degradation as assessed by a new urinary marker. Increased urinary CTX-II levels are associated with rapidly destructive disease, suggesting that this marker might be useful in identifying patients with hip OA at high risk for rapid progression of joint damage.
Authors: T Conrozier; M Lequesne; H Favret; A Taccoen; B Mazières; M Dougados; M Vignon; E Vignon Journal: Osteoarthritis Cartilage Date: 2001-04 Impact factor: 6.576
Authors: J T Downs; C L Lane; N B Nestor; T J McLellan; M A Kelly; G A Karam; P S Mezes; J P Pelletier; I G Otterness Journal: J Immunol Methods Date: 2001-01-01 Impact factor: 2.303
Authors: Patrick Garnero; Xavier Ayral; Jean-Charles Rousseau; S Christgau; Linda J Sandell; Maxime Dougados; Pierre D Delmas Journal: Arthritis Rheum Date: 2002-10
Authors: X Chevalier; T Conrozier; M Gehrmann; P Claudepierre; P Mathieu; S Unger; E Vignon Journal: Osteoarthritis Cartilage Date: 2001-05 Impact factor: 6.576
Authors: Jeffrey J Nepple; Kayla M Thomason; Tonya W An; Marcie Harris-Hayes; John C Clohisy Journal: Clin Orthop Relat Res Date: 2015-05 Impact factor: 4.176
Authors: A P Goode; S W Marshall; V B Kraus; J B Renner; T Stürmer; T S Carey; D E Irwin; J M Jordan Journal: Osteoarthritis Cartilage Date: 2012-08-10 Impact factor: 6.576
Authors: I Meulenbelt; M Kloppenburg; H M Kroon; J J Houwing-Duistermaat; P Garnero; M-P Hellio Le Graverand; J Degroot; P E Slagboom Journal: Ann Rheum Dis Date: 2005-08-03 Impact factor: 19.103